ADVANCE SOLID TUMORS
Clinical trials for ADVANCE SOLID TUMORS explained in plain language.
Never miss a new study
Get alerted when new ADVANCE SOLID TUMORS trials appear
Sign up with your email to follow new studies for ADVANCE SOLID TUMORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug INV-8989 targets Hard-to-Treat cancers with KRAS G12D mutation
Disease control Recruiting nowThis study tests a new drug called INV-8989 in people with advanced solid tumors that have a specific genetic change called KRAS G12D. The trial has two phases: the first finds the safest dose, and the second checks how well the drug shrinks tumors. About 178 adults with cancers …
Matched conditions: ADVANCE SOLID TUMORS
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Ionova Life Sciences Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New Antibody-Drug conjugate KIVU-107 enters first human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called KIVU-107 in 76 adults with advanced solid tumors that have not responded to standard treatments. KIVU-107 is an antibody-drug conjugate designed to target and kill cancer cells. The main goal is to find a safe dose and check for side…
Matched conditions: ADVANCE SOLID TUMORS
Phase: PHASE1 • Sponsor: Kivu Bioscience Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC